CLINICAL TRIALS AND OBSERVATIONS Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia
نویسندگان
چکیده
Tadeusz Robak,1 Jerzy Windyga,2 Jacek Trelinski,1 Mario von Depka Prondzinski,3 Aristoteles Giagounidis,4 Chantal Doyen,5 Ann Janssens,6 María Teresa Álvarez-Román,7 Isidro Jarque,8 Javier Loscertales,9 Gloria Pérez Rus,10 Andrzej Hellmann,11 Wiesław Wiktor Jêdrzejczak,12 Kazimierz Kuliczkowski,13 Lana M. Golubovic,14 Dusica Celeketic,15 Andrei Cucuianu,16 Emanuil Gheorghita,17 Mihaela Lazaroiu,17 Ofer Shpilberg,18 Dina Attias,19 Elena Karyagina,20 Kalinina Svetlana,21 Kateryna Vilchevska,22 Nichola Cooper,23 Kate Talks,24 Mukhyaprana Prabhu,25 Prasad Sripada,26 T. P. R. Bharadwaj,27 Henrik Næsted,28 Niels J. Ø. Skartved,28 Torben P. Frandsen,28 Mimi F. Flensburg,28 Peter S. Andersen,28 and Jørgen Petersen28
منابع مشابه
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the Fc RIIA and Fc IIIA genes
A single recombinant immunoglobulin G1 (IgG1) anti-RhD antibody (MonoRho) was compared with a currently used polyclonal anti-RhD product (Rhophylac) in a phase 1 study for safety, efficacy of Rhesus D (RhD)–positive red blood cell (RBC) clearance, and prevention of RhD immunization in RhD-negative men challenged with 15 mL RhD-positive RBCs. Both the polyclonal product and recombinant antiRhD e...
متن کاملSpotlight on anti-CD25: daclizumab in MS.
Monoclonal antibodies are a promising new class of therapeutic agents that can be employed to target specific molecules of the immune system or any tissue. They are currently being tested in a number of clinical trials in autoimmune diseases such as multiple sclerosis (MS). One of these, the humanized monoclonal anti-CD25 antibody daclizumab (Zenapax), is directed against the interleukin-2 (IL-...
متن کاملThe preferential expression of CD7 and CD34 in myeloid blast crisis in chronic myeloid leukemia.
karyocyte colony formation. These data indicate that the IgG autoantibodies can specifically neutralize the in vitro biologic activity of TPO. The effectiveness of cyA in improving thrombocytopenia strongly suggests an immune-mediated pathogenetic mechanism in the patient. Although it is unclear that anti-TPO autoantibody is the sole cause of the thrombocytopenia, the recovery of serum TPO leve...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphoma
Idiotype vaccination for follicular lymphoma is primarily being developed as remission consolidation after chemotherapy. We investigated idiotype vaccination as primary intervention for treatmentnaive indolent B-cell lymphoma and in a separate cohort as remission consolidation after chemotherapy to assess immunization-induced immune responses in relation to progression-free survival (German Cli...
متن کاملCCL2 blockade augments cancer immunotherapy.
Altering the immunosuppressive microenvironment that exists within a tumor will likely be necessary for cancer vaccines to trigger an effective antitumor response. Monocyte chemoattractant proteins (such as CCL2) are produced by many tumors and have both direct and indirect immunoinhibitory effects. We hypothesized that CCL2 blockade would reduce immunosuppression and augment vaccine immunother...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2012